Drug Trial Radar · NCT00272948
Pediatric Trial Investigating the Incidence & Outcome of Veno-Occlusive Disease With the Prophylactic Use of Defibrotide
Last checked: Nov 20, 2026Latest source record: Jun 9, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
360
Planned (sponsor's estimate)
Start
Dec 2005
Primary completion
Jan 2009
Study completion Jul 2009
Sponsor
- Lead sponsor
- European Society for Blood and Marrow TransplantationResearch network
- Sponsor type
- Research network
- Collaborators
- Jazz Pharmaceuticals; Deutsche Krebshilfe e.V., Bonn (Germany)
- First posted
- Jan 9, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this trial is to evaluate whether the prophylactic use of Defibrotide (DF) in pediatric patients (age less than 18 years) undergoing stem cell transplantation and who are at high risk of developing hepatic Veno-occlusive Disease (VOD) will have an impact on the incidence and severity of the disease. Patients will be randomly assigned to one of two treatment arms: Those allocated to the Prophylactic Arm will receive the study drug (Defibrotide) from the day of conditioning onwards. Patients allocated to the Control Arm will receive the study drug (Defibrotide) from the day that VOD is diagnosed.
Conditions
- Hepatic Veno-Occlusive Disease
Interventions
DefibrotideDrug
Defibrotide 25 mg/kg/d
DefibrotideDrug
Defibrotide 25 mg/kg/d iv in 4 doses beginning at day of conditioning until day +30 or until discharge from inpatient care (with a minimum treatment of 14 days) if VOD does not occur.
DefibrotideDrug
Defibrotide 25 mg/kg/d iv therapeutically when patients fulfil modified Seattle criteria
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary objective is to evaluate if prophylactic DF has an impact on the incidence of VODTime frame: Day + 30 post HSCT
Locations
30 sites in 10 countries. Site status is shown where the registry gives one.
University Hospital
Graz, Austria
St Anna Kinderspital
Vienna, Austria
Inst. Gustave Roussy
Villejuif, France
University Hospital
Dresden, Germany
Klinik Kinder-Onkologie
Düsseldorf, Germany
Johann-Wolfgang Goethe Universität
Frankfurt, Germany
Universitätsspital Eppendorf
Hamburg, Germany
Medical School
Hanover, Germany
University Hospital
Heidelberg, Germany
Kinderklinik
Jena, Germany
Christian-Albrecht -University
Kiel, Germany
Kinderpoliklinik Uni
München, Germany
Poliklinik Kinderheilkunde
Münster, Germany
Universitätsspital
Tübingen, Germany
Our Lady's Hospital for Sick Children
Dublin, Ireland
Schneider Children's MC
Petah Tikva, Israel
Institute G. Gaslini
Genova, Italy
Ospedale S. Gerardo
Monza, Italy
Clinica di Oncoematologia Pediatrica
Padova, Italy
University Hospital
Utrecht, Netherlands
Sahlgrenska University Hospital
Gothenburg, Sweden
University Hospital
Huddinge, Sweden
University Hospital
Lund, Sweden
University Hospital
Uppsala, Sweden
University Children Hospital
Basel, Switzerland
Inselspital
Bern, Switzerland
Hopital Cantonal Universitaire
Geneva, Switzerland
University Hospital
Zurich, Switzerland
Great Ormond Street Hospital
London, United Kingdom
Children's Hospital
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.